CN118251225A - 治疗神经退行性疾病的方法 - Google Patents

治疗神经退行性疾病的方法 Download PDF

Info

Publication number
CN118251225A
CN118251225A CN202280074005.1A CN202280074005A CN118251225A CN 118251225 A CN118251225 A CN 118251225A CN 202280074005 A CN202280074005 A CN 202280074005A CN 118251225 A CN118251225 A CN 118251225A
Authority
CN
China
Prior art keywords
methyl
pyrrolo
pyrimidin
chloro
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280074005.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·巴拉萨
J·K·特里默
Y·余
X·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of CN118251225A publication Critical patent/CN118251225A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202280074005.1A 2021-09-07 2022-09-06 治疗神经退行性疾病的方法 Pending CN118251225A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163260942P 2021-09-07 2021-09-07
US63/260,942 2021-09-07
PCT/US2022/075966 WO2023039368A1 (en) 2021-09-07 2022-09-06 Methods for treating neurogenerative diseases

Publications (1)

Publication Number Publication Date
CN118251225A true CN118251225A (zh) 2024-06-25

Family

ID=85506882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280074005.1A Pending CN118251225A (zh) 2021-09-07 2022-09-06 治疗神经退行性疾病的方法

Country Status (7)

Country Link
US (1) US20240382491A1 (https=)
EP (1) EP4398986A4 (https=)
JP (1) JP2024533263A (https=)
CN (1) CN118251225A (https=)
CA (1) CA3230996A1 (https=)
MX (1) MX2024002886A (https=)
WO (1) WO2023039368A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012656A2 (en) * 2010-07-21 2012-01-26 University Of South Florida Materials and methods for treating neurodegenerative diseases
EP2867236B1 (en) * 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Also Published As

Publication number Publication date
EP4398986A1 (en) 2024-07-17
WO2023039368A1 (en) 2023-03-16
CA3230996A1 (en) 2023-03-16
JP2024533263A (ja) 2024-09-12
MX2024002886A (es) 2024-05-24
US20240382491A1 (en) 2024-11-21
EP4398986A4 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
EP4288441A1 (en) Methods for treating spinocerebellar ataxia type 3
US12398140B2 (en) Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
US12286420B2 (en) EAAT2 activators and methods of using thereof
WO2017123991A1 (en) Pyridazine derivatives as eaat2 activators
WO2022169868A1 (en) Compounds for treating spinocerebellar ataxia type 3
WO2019014460A1 (en) MOLECULES ENHANCING EAAT2
CN118251225A (zh) 治疗神经退行性疾病的方法
US20210269442A1 (en) Fused ring derivative used as fgfr4 inhibitor
CN118019531A (zh) 用于治疗神经退行性疾病的方法
CN118401243A (zh) 治疗神经退行性疾病的方法
CN115515682B (zh) 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
US20240051968A1 (en) Methods for treating spinocerebellar ataxia type 3
US20240041886A1 (en) Methods for treating spinocerebellar ataxia type 3
US20250129080A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
HK40042691B (en) Eaat2 activators and methods of using thereof
HK40042691A (en) Eaat2 activators and methods of using thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination